Celadon Pharmaceuticals PLC ( (GB:CEL) ) has shared an update.
Celadon Pharmaceuticals Plc has announced significant board changes and a proposal to de-list from AIM, driven by CEO James Short’s belief that it will reduce operational costs and provide better access to capital. Following the resignation of four non-executive directors, the company plans to propose the cancellation of its ordinary shares trading on AIM, with arrangements for a Matched Bargain Facility to assist shareholders in trading shares if the de-listing is approved. Chairman Alexander Anton may resign if the de-listing proceeds.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions such as autism. Celadon operates a 100,000 sq. ft EU-GMP approved facility in the UK, which includes indoor hydroponic cultivation, GMP extraction, and an R&D laboratory. The company holds a Home Office license for the commercial supply of pharmaceutical-grade cannabis and has an approved clinical trial for treating chronic pain in the UK.
YTD Price Performance: -6.67%
Average Trading Volume: 209,815
Technical Sentiment Signal: Buy
Current Market Cap: £9.64M
See more data about CEL stock on TipRanks’ Stock Analysis page.